Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 15, 2024HaematologicaOpen Access

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

View Full Paper
Ask AI
Bookmark
Share

Authors

VGVerónica González‐CallePRPaula Rodríguez‐OteroASAnna Sureda

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

González‐Calle et al. (2024) studied this question.

synapsesocial.com/papers/68e78f66b6db643587701113https://doi.org/10.3324/haematol.2023.284089
View Full Paper
Ask AI
Bookmark
Share